The drugmaker posted stronger-than-expected Q4 earnings. The company boosted the full-year sales forecast
Moderna
posted diluted GAAP (generally accepted accounting principles) earnings per
share of $11.29 for the three months ending in December. The figures are
significantly higher than the 69 cents per share loss reported in the year-ago
period. Group revenues also topped expectations, coming in at $7.21 billion.
For the whole year, the company announced sales of $18.5 billion for 2021,
significantly higher than the $803 million reported for 2020.
Moderna executives mentioned that they believe a fourth
COVID-19 vaccine shot will be needed late this year due to waning protection
from previous doses. This could push up sales in the second half of 2022. CEO
Stephane Bancel stressed that Moderna’s current deals projections for Spikevax
COVID-19 shot don’t include any additional sales in the US this year. The
figures are expected to be at $19 billion in 2022. Orders for its vaccine have
been confirmed for 2023 from Canada, the UK, and Taiwan.
Moderna’s stock price closed 15.10% higher, at $156.23 per
share as of Thursday.
Sources: finance.yahoo.com, thestreet.com
